Recursion Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.72 | -$0.11 | -$0.42 |
| Q2 2024 | 2 | -$0.65 | -$0.10 | -$0.38 |
| Q3 2024 | 3 | -$0.57 | -$0.09 | -$0.33 |
| Q4 2024 | 5 | -$0.51 | -$0.35 | -$0.42 |
| Q1 2025 | 2 | -$0.82 | -$0.13 | -$0.48 |
| Q2 2025 | 1 | -$0.82 | -$0.13 | -$0.49 |
| Q3 2025 | 1 | -$0.84 | -$0.13 | -$0.49 |
| Q4 2025 | 1 | -$0.82 | -$0.13 | -$0.48 |
| Q1 2026 | 1 | -$0.59 | -$0.09 | -$0.35 |
| Q2 2026 | 1 | -$0.61 | -$0.09 | -$0.36 |
| Q3 2026 | 1 | -$0.44 | -$0.07 | -$0.26 |
| Q4 2026 | 1 | -$0.49 | -$0.08 | -$0.29 |
Recursion Pharmaceuticals, Inc. Earnings Date And Information
Recursion Pharmaceuticals, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.34 earnings per share for the quarter, topping analysts' consensus estimates of $-0.35 by $0.01. The company had revenue of 26.08 M for the quarter and had revenue of 44.58 M for the year. Recursion Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-1.58 diluted earnings per share) and currently has a price-to-earnings ratio of -5.17. Recursion Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Recursion Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.35 | -$0.34 | 0.01 | $18.72 M | $26.08 M |
| 08/08/2024 | Q2 2024 | -$0.35 | -$0.40 | -0.05 | $11.96 M | $14.42 M |
| 05/09/2024 | Q1 2024 | -$0.43 | -$0.39 | 0.04 | $13.79 M | |
| 02/29/2024 | Q4 2023 | -$0.40 | $10.89 M | |||
| 11/09/2023 | Q3 2023 | -$0.38 | -$0.43 | -0.05 | $11.24 M | $10.10 M |
| 08/08/2023 | Q2 2023 | -$0.38 | -$0.38 | 0 | $11.87 M | $11.02 M |
| 05/08/2023 | Q1 2023 | -$0.34 | -$0.32 | 0.02 | $12.13 M | |
| 02/27/2023 | Q4 2022 | -$0.15 | -$0.31 | -0.16 | $13.68 M | |
| 11/08/2022 | Q3 2022 | -$0.36 | -$0.34 | 0.02 | $6.84 M | $13.05 M |
| 08/09/2022 | Q2 2022 | -$0.35 | -$0.38 | -0.03 | $5.33 M | $7.65 M |
| 05/10/2022 | Q1 2022 | $0.51 | -$0.33 | -0.84 | $5.30 M | |
| 03/23/2022 | Q4 2021 | -$0.30 | -$0.38 | -0.08 | $2.50 M | |
| 11/10/2021 | Q3 2021 | -$0.28 | -$0.28 | 0 | $2.68 M | $2.50 M |
| 08/13/2021 | Q2 2021 | -$0.23 | -$0.26 | -0.03 | $2.73 M | $2.50 M |
| 05/12/2021 | Q1 2021 | -$0.18 | $2.50 M | |||
| 12/31/2020 | Q4 2020 | -$0.15 | $2.55 M | |||
| 09/29/2020 | Q3 2020 | -$0.14 | $862,000 | |||
| 06/29/2020 | Q2 2020 | -$0.11 | $186,000 | |||
| 03/30/2020 | Q1 2020 | -$0.11 | $60,000 |
Recursion Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Recursion Pharmaceuticals, Inc.'s earnings date?
Recursion Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
-
Did Recursion Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Recursion Pharmaceuticals, Inc. (:RXRX) reported $-0.34 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.35 by $0.01.
-
How can I listen to Recursion Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Recursion Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Recursion Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Recursion Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Recursion Pharmaceuticals, Inc. generate each year?
Recursion Pharmaceuticals, Inc. (:RXRX) has a recorded annual revenue of $44.58 M.
-
How much profit does Recursion Pharmaceuticals, Inc. generate each year?
Recursion Pharmaceuticals, Inc. (:RXRX) has a recorded net income of $44.58 M. Recursion Pharmaceuticals, Inc. has generated $-1.58 earnings per share over the last four quarters.
-
What is Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio?
Recursion Pharmaceuticals, Inc. (:RXRX) has a price-to-earnings ratio of -5.17 and price/earnings-to-growth ratio is -0.19.
